NHE3 Inhibitors for IBS-C: A Study Author’s Perspective

Physician’s Weekly recently spoke with William D. Chey, MD, FACG, AGAF, FACP, RFF, lead author of the phase 3 T3MPO-2 study—which assessed the efficacy of the NHE3 inhibitor tenapanor in treating patients with irritable bowel syndrome with constipation (IBS-C)—about NHE3 inhibitors and their unique method of action (MOA) in treating patients with IBS-C.

Read More
  • 1
  • 2

For latest news and updates
Email-id is invalid